Cognitive event-related potentials in multiple sclerosis: Correlation with MRI and neuropsychological findings

Kimiskidis, Vasilios Κ.; Papaliagkas, Vasileios; Sotirakoglou, Κyriaki; Kouvatsou, Zoi; Kapina, Victoria K.; Papadaki, Efrosini; Tsimourtou, Vana; Masoura, Elvira; Kazis, Dimitrios; Papayiannopoulos, Sotirios; Geroukis, Triantafyllos; Bostanjopoulou, Sevasti

doi:10.1016/j.msard.2016.10.006

Cited by 20 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cognitive event-related potentials (ERPs), mainly the P300 component, are significantly correlated with neuropsychological performance, 133,134 as well as with MRI lesion load. 135 In the latter study, discriminant analysis based on combined MRI and ERPs could classify 79.63% of patients in RR, PP, and SP subgroups. In MS, a good test-retest consistency has been demonstrated for topography.…”

Section: Electrophysiological Outcomesmentioning

confidence: 87%

Fluid biomarker and electrophysiological outcome measures for progressive MS trials

et al. 2017

View full text Add to dashboard Cite

Progressive multiple sclerosis (MS) is characterized by insidious clinical worsening that is difficult to accurately quantify and predict. Biofluid markers and electrophysiological measures are potential candidate outcome measures in clinical trials, allowing the quantification of nervous damage occurring in the disease. Neurofilaments are highly specific neuronal proteins. They may have come closest to such applications by their higher concentrations repeatedly demonstrated in cerebrospinal fluid (CSF) in all stages of MS, during relapses, their responsiveness to disease-modifying treatments in relapsing and progressive MS and their associations with measures of inflammatory and degenerative magnetic resonance imaging (MRI) outcomes. Digital single-molecule array (Simoa) technology improves accuracy of bioassays in the quantification of neurofilament light chain (NfL) in serum and plasma. NfL seems to mark a common final path of neuroaxonal injury independent of specific causal pathways. CSF and blood levels of NfL are highly correlated across various diseases including MS, suggesting that blood measurements may be useful in assessing response to treatment and predicting future disease activity. Other biomarkers like matrix metalloproteinases, chemokines, or neurotrophic factors have not been studied to a similar extent. Such measures, especially in blood, need further validation to enter the trial arena or clinical practice. The broadening armamentarium of highly sensitive assay technologies in the future may shed even more light on patient heterogeneity and mechanisms leading to disability in MS. Evoked potentials (EPs) are used in clinical practice to measure central conduction of central sensorimotor pathways. They correlate with and predict the severity of clinical involvement of their corresponding function. Their validation for use in multicenter studies is still lacking, with the exception of visual EPs. If further validated, EPs and fluid biomarkers would represent useful outcome measures for clinical trials, being related to specific mechanisms of the ongoing pathologic changes.

show abstract

Section: Electrophysiological Outcomesmentioning

confidence: 87%

Fluid biomarker and electrophysiological outcome measures for progressive MS trials

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In summary, majority of analyses confirmed that patients with NMOSD scored significantly lower in cognitive tests than HC. Deficits in attention, memory, processing speed, verbal fluency, verbal learning, and executive function are considered to be the most frequent in this group of patients (Blanc et al., 2008; Chanson et al., 2011; He, Wu, et al, 2011; Hollinger et al., 2016; Kawahara et al., 2014; Kimiskidis et al., 2016; Vanotti et al., 2013; Wang et al, 2017; Zhang et al., 2015), as shown in Table 1.…”

Section: Cognitive Impairment Profile In Patients With Nmosdmentioning

confidence: 99%

Cognitive impairment in NMOSD—More questions than answers

et al. 2020

View full text Add to dashboard Cite

Since the first cases of neuromyelitis optica (NMO) had been described by Eugene Devic in 1894, the understanding of pathogenesis and clinical presentations of the disease broadened considerably (Wingerchuk et al., 2015). The discovery of an association of NMO with the presence of serum antibodies against aquaporin 4 (AQP4) facilitated the diagnostic process of the disease and allowed for better differentiation between NMO and multiple sclerosis (MS) variants. In the central nervous system (CNS), the water channel AQP4, involved in the processes of osmoregulation, is highly expressed on astrocytic end-feet (forming part of the blood-brain barrier)

show abstract

“…In one study, T1 hypointense lesions were shown to correlate with Stroop test performance [34]. In another study, which analysed cognitive event-related potentials (ERPs), white matter degenerative lesion volume was associated with semantic and phonemic verbal fluency [14]. Both the Stroop test and the verbal fluency test require high performance in executive functions.…”

Section: Discussionmentioning

confidence: 99%

“…In the course of multiple sclerosis, 40-70% of patients develop cognitive dysfunction [13]. The most commonly observed deficits related to MS include executive dysfunction, low verbal fluency, and difficulties in visuospatial performance, short-term memory, abstract reasoning and attention [14][15]. These may be accompanied or related to depression or general fatigue.…”

Section: Introductionmentioning

confidence: 99%

Spatial distribution of white matter degenerative lesions and cognitive dysfunction in relapsing-remitting multiple sclerosis patients

Nowaczyk

Kalinowska-Łyszczarz

Paprzycki

et al. 2018

Neurol Neurochir Pol.

View full text Add to dashboard Cite

Aim. The aim of this study was to assess degenerative lesion localisation in the course of relapsing-remitting multiple sclerosis (RRMS) and to identify the association between localisation and the frequency of T1-hypointense lesions (black holes) with cognitive dysfunction. We also searched for neuroradiological predictors of cognitive dysfunction in patients. The clinical rationale for the study was previous research, and our own findings suggest that lesion localisation plays an important role in cognitive performance and neurological disability of MS patients. Material and methods. Forty-two patients were included in the study. All subjects underwent neuropsychological examination using Raven's Coloured Progressive Matrices, a naming task from the Brief Repeatable Battery of Neuropsychological Tests, and attention to detail tests. Magnetic resonance imaging (MRI) was acquired on 1.5 Tesla scanner and black holes were manually segmented on T1-weighted volumetric images using the FMRIB Software Library. Linear regression was applied to establish a relationship between black hole volume per lobe and cognitive parameters. Bonferroni correction of voxelwise analysis was used to correct for multiple comparisons. Results. The following associations between black hole volume and cognition were identified: frontal lobes black hole volume was associated with phonemic verbal fluency (t =-4.013, p < 0.001), parietal black hole volume was associated with attention (t =-3.776, p < 0.001), and parietal and temporal black hole volumes were associated with nonverbal intelligence (p < 0.001). The volume of parietal black holes was the best predictor of cognitive dysfunction. Conclusions. Our approach, including measurement of focal axonal loss based on T1-volumetric MRI sequence and brief neuropsychological assessment, might improve personalised diagnostic and therapeutic decisions in clinical practice.

show abstract

Cognitive event-related potentials in multiple sclerosis: Correlation with MRI and neuropsychological findings

Cited by 20 publications

References 22 publications

Fluid biomarker and electrophysiological outcome measures for progressive MS trials

Fluid biomarker and electrophysiological outcome measures for progressive MS trials

Cognitive impairment in NMOSD—More questions than answers

Spatial distribution of white matter degenerative lesions and cognitive dysfunction in relapsing-remitting multiple sclerosis patients

Contact Info

Product

Resources

About